Carboplatin - PharmaKB

Carboplatin

Carboplatin (carboplatin) is a small molecule pharmaceutical. Carboplatin was first approved as Paraplatin on 1989-03-03. It is used to treat bone marrow diseases, breast neoplasms, central nervous system neoplasms, endometrial neoplasms, and esophageal neoplasms amongst others in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
neoplasms	D009369
digestive system diseases	D004066
respiratory tract diseases	D012140
nervous system diseases	D009422
urogenital diseases	D000091642
hemic and lymphatic diseases	D006425
skin and connective tissue diseases	D017437
endocrine system diseases	D004700

Trade Name

FDA

EMA

Carboplatin (discontinued: Carboplatin, Paraplatin)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Carboplatin

Tradename	Company	Number	Date	Products
PARAPLATIN	CordenPharma	N-019880 DISCN	1989-03-03	3 products, RLD
PARAPLATIN	CordenPharma	N-020452 DISCN	2003-07-14	4 products, RLD

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
carboplatin	ANDA	2024-10-04
paraplatin	ANDA	2022-08-19

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
breast neoplasms	EFO_0003869	D001943	C50
ovarian neoplasms	EFO_0003893	D010051	C56
endometrial neoplasms	EFO_0004230	D016889	—
esophageal neoplasms	—	D004938	C15
lung neoplasms	HP_0100526	D008175	C34.90
urinary bladder neoplasms	—	D001749	C67
osteosarcoma	—	D012516	—
central nervous system neoplasms	—	D016543	—
germ cell and embryonal neoplasms	—	D009373	—
bone marrow diseases	—	D001855	—

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

L: Antineoplastic and immunomodulating agents

— L01: Antineoplastic agents

— L01X: Other antineoplastic agents in atc

— L01XA: Platinum compounds, antineoplastic drugs

— L01XA02: Carboplatin

HCPCS

Code	Description
J9045	Injection, carboplatin, 50 mg

Clinical

Clinical Trials

3696 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Non-small-cell lung carcinoma	D002289	—	—	234	600	290	13	52	1078
Lung neoplasms	D008175	HP_0100526	C34.90	220	628	264	13	58	1072
Ovarian neoplasms	D010051	EFO_0003893	C56	148	255	98	4	29	466
Breast neoplasms	D001943	EFO_0003869	C50	85	280	88	9	36	450
Carcinoma	D002277	—	C80.0	99	287	77	2	22	448
Neoplasms	D009369	—	C80	254	141	28	2	15	379
Ovarian epithelial carcinoma	D000077216	—	—	101	185	72	4	22	338
Small cell lung carcinoma	D055752	—	—	57	151	48	3	16	244
Squamous cell carcinoma	D002294	—	—	41	148	34	2	10	216
Triple negative breast neoplasms	D064726	—	—	36	116	38	2	6	177

Show 26 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Fallopian tube neoplasms	D005185	—	—	67	83	45	—	6	176
Uterine cervical neoplasms	D002583	HP_0030159	—	22	48	30	—	11	100
Head and neck neoplasms	D006258	—	—	27	70	15	—	3	98
Endometrial neoplasms	D016889	EFO_0004230	—	30	54	19	—	5	96
Peritoneal neoplasms	D010534	—	—	29	43	23	—	5	88
Esophageal squamous cell carcinoma	D000077277	—	—	10	44	11	—	6	63
Neuroblastoma	D009447	EFO_0000621	—	13	27	20	—	4	60
Prostatic neoplasms	D011471	—	C61	16	43	3	—	—	55
Central nervous system neoplasms	D016543	—	—	19	31	7	—	6	55
Transitional cell carcinoma	D002295	—	—	12	25	16	—	2	51

Show 139 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Pancreatic neoplasms	D010190	EFO_0003860	C25	13	10	—	—	1	22
Male breast neoplasms	D018567	—	—	6	5	—	—	4	14
Uterine neoplasms	D014594	EFO_0003859	C55	4	11	—	—	1	14
Immunotherapy	D007167	—	—	1	11	—	—	1	12
Pancreatic ductal carcinoma	D021441	—	—	8	4	—	—	—	10
T-cell lymphoma	D016399	—	—	5	6	—	—	1	10
T-cell lymphoma peripheral	D016411	—	—	5	6	—	—	1	10
Follicular lymphoma	D008224	—	C82	5	7	—	—	1	10
Papilloma	D010212	—	—	2	8	—	—	—	9
Precursor cell lymphoblastic leukemia-lymphoma	D054198	—	—	4	4	—	—	1	8

Show 180 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hematologic neoplasms	D019337	—	—	3	—	—	—	—	3
Rectal neoplasms	D012004	—	—	1	—	—	—	1	2
Infections	D007239	EFO_0000544	—	2	—	—	—	—	2
Communicable diseases	D003141	—	—	2	—	—	—	—	2
Pharmacokinetics	D010599	—	—	2	—	—	—	—	2
Myeloid leukemia chronic-phase	D015466	—	—	1	—	—	—	—	1
Myeloid leukemia accelerated phase	D015465	—	—	1	—	—	—	—	1
Blast crisis	D001752	—	—	1	—	—	—	—	1
Tumor virus infections	D014412	—	—	1	—	—	—	—	1
And serous mucinous cystic neoplasms	D018297	—	—	1	—	—	—	—	1

Show 28 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Methylation	D008745	—	—	—	—	—	—	1	1
Hypoxia	D000860	HP_0012418	R09.02	—	—	—	—	1	1
Immunoglobulin light-chain amyloidosis	D000075363	—	—	—	—	—	—	1	1
Amyloidosis	D000686	EFO_1001875	E85	—	—	—	—	1	1
Primitive neuroectodermal tumors peripheral	D018241	—	—	—	—	—	—	1	1
Taste disorders	D013651	—	—	—	—	—	—	1	1
Dysgeusia	D004408	—	R43.2	—	—	—	—	1	1
Ageusia	D000370	EFO_1001758	—	—	—	—	—	1	1
Breast diseases	D001941	—	N60-N65	—	—	—	—	1	1
Observation	D019370	—	—	—	—	—	—	1	1

Show 16 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Carboplatin
INN	carboplatin
Description	Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Classification	Small molecule
Drug class	antineoplastics (platinum derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—